Insilico Medicine has entered into a multi-year research collaboration with Servier potentially worth up to USD 888 million, combining its AI-driven Pharma.AI platform with Servier's oncology development expertise. Under the agreement, Insilico is eligible to receive up to USD 32 million in upfront and near-term R&D milestone payments. The company will use its AI platform to identify and advance potential drug candidates, while Servier will co-share R&D costs and lead subsequent clinical development and global commercialisation for promising oncology assets.

This deal follows Insilico's successful Hong Kong IPO in December 2025 and continues its established strategy of forming strategic partnerships. The company has previously secured multiple high-value collaborations, including three pipeline out-licensing deals with a potential total value of USD 2.1 billion and R&D partnerships with pharmaceutical giants such as Sanofi, Eli Lilly and Fosun Pharma. These agreements validate the commercial utility of its AI platform and contribute to a sustainable business model alongside its internal pipeline development.

According to PharmCube's NextBiopharm® database, this is the second-largest deal between Insilico and an overseas company. Click here to request a free trial for NextBiopharm®.